TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11952026
Drug: IM ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM ceftriaxone 1 g once daily
Study: 10075344
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g raw flaxseed
Study: 10075344
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g raw flaxseed
Study: 10075344
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g raw flaxseed
Study: 10075344
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g processed flaxseed (muffin or bread)
Study: 10075344
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g flaxseed (raw or processed)
Study: 2027481
Drug: Low-dose prednisone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prednisone (0.75 mg/kg/d)
Study: 2027481
Drug: High-dose prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prednisone (1.5 mg/kg/d)
Study: 30651222
Drug: SIT-STAND (sitting
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIT-STAND (sitting with hourly 10-min standing interruptions)
Study: 25212541
Drug: Pharmacist counselling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist counselling before starting chemotherapy
Study: 25212541
Drug: Follow-up with
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up with the pharmacist after starting chemotherapy
Study: 17114889
Drug: Sublingual-swallow immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual-swallow immunotherapy (SLIT) with Juniperus ashei allergen extract
Study: 16394701
Drug: 550 mg
Normalized name: xylitol 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 550 mg naproxen
Study: 15383182
Drug: Captodiamine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captodiamine (150 mg/d)
Study: 10735891
Drug: Suramin plus
Normalized name: suramin
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suramin plus hydrocortisone (HC, 40 mg/d)
Study: 8923333
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg of doxylamine succinate administered orally every 6 h for 17 days
Study: 8923333
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of phenobarbital administered orally every 6 h for 17 days
Study: 8923333
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally every 6 h for 17 days
Study: 4053337
Drug: Slow inspiratory
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow inspiratory flow rates (15-30 l/min)
Study: 4053337
Drug: Flow rates
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flow rates higher than 70 l/min
Study: 26250523
Drug: Thymosin α1
Normalized name: chymosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymosin α1 (Tα1) plus routine treatment
Study: 24081937
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg once per day
Study: 24297950
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg twice per day
Study: 21694621
Drug: Antidepressant use
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant use (citalopram, sertraline, paroxetine)
Study: 21694621
Drug: No antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antidepressant use
Study: 12597703
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg MPH
Study: 12597703
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg MPH
Study: 18582178
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg MPH
Study: 16538239
Drug: Olibra fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olibra fat emulsion (5 g of Olibra fat)
Study: 16538239
Drug: Control (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (5 g milk fat)
Study: 8836933
Drug: Sustained-release (SR)
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release (SR) levodopa preparation (100 mg and 200 mg)
Study: 8836933
Drug: Conventional immediate-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immediate-release (IR) levodopa preparation (100 mg)
Study: 8836933
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of SR and IR levodopa (70% SR and 30% IR)
Study: 1417666
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E administration at a dose of 100 mg daily for three weeks
Study: 1417666
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A administration
Study: 23756453
Drug: Goal-Directed Therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-Directed Therapy (GDT)
Study: 24474602
Drug: TAU+P (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU+P (treatment as usual combined with clinician-lead cognitive behavioural treatment for perfectionism)
Study: 21965526
Drug: Aliskiren (direct
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (direct renin inhibitor), n=423
Study: 27936941
Drug: Aliskiren (direct
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (direct renin inhibitor)
Study: 11765586
Drug: Metformin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (2 × 850 mg/day)
Study: 11765586
Drug: Acarbose (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (3 × 100 mg/day)
Study: 12475829
Drug: Enoxaparin, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin, 40 mg/d
Study: 12475829
Drug: Heparin, 5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin, 5,000 U bid
Study: 6957982
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg PIR twice daily
Study: 31207152
Drug: Live Zoster
Normalized name: Varicella zoster vaccine (live/attenuated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live Zoster Vaccine (LZV)
Study: 31207152
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg BID plus MTX
Study: 31207152
Drug: Adalimumab (ADA)
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab (ADA) 40 mg every other week plus MTX
Study: 19140095
Drug: 360 mg
Normalized name: aspirin 360 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mg verapamil daily for 6 days
Study: 10750752
Drug: hANP (human
Approvals — FDA: no, EMA: no, PMDA: no
Description: hANP (human atrial natriuretic peptide) administered for 24 hours from the start of CPB
Study: 4025853
Drug: Etomidate (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (0.4 mg/kg)
Study: 1529939
Drug: Fruits and
Normalized name: Aminobenzoic Acid/Ascorbic Acid/Biotin/Calcium/Cholecalciferol/Choline Bitartrate/Copper/Cyanocobalamin/Folic Acid/Inositol/Iodine/Iron/Magnesium/Manganese/Niacin/Pantothenic Acid/Phosphorus/Pyridoxine/Riboflavin/Thiamine/Vitamin A/Vitamin E/Zinc 5 MG-180 MG-300 MCG-120 MG-30 MCG-5 MG-2 MG-18 MCG-800 MCG-5 MG-150 MCG-18 MG-100 MG-2 MG-20 MG-30 MG-15 MG-2 MG-5.1 MG-4.5 MG-2250 MCG-7 MG-5 MG Oral Tablet [MEGAVITE WITH FRUITS AND VEGGIES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruits and vegetables (administered for 12 weeks)
Study: 4074606
Drug: Felodipine 10
Normalized name: felodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 10 mg oral solution
Study: 3304706
Drug: Timolol (5.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol (5.5 mg iv as a bolus divided into four doses during the first 2 hours followed by 10 mg orally twice daily for 1 month)
Study: 28288611
Drug: Resistance exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance exercise (twice weekly for 15 weeks)
Study: 25774705
Drug: Low-glycaemic-index (LGI)
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-glycaemic-index (LGI) diet and Policaptil Gel Retard
Study: 20534951
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole solution mixed with orange juice
Study: 20534951
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole solution with water
Study: 18503623
Drug: Levobupivacaine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 3 mg/mL
Study: 18503623
Drug: Ropivacaine 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 4.5 mg/mL
Study: 18503623
Drug: Bupivacaine 3
Normalized name: BUPivacaine 300 MG / meloxicam 9 MG in 10.5 ML Extended Release Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 3 mg/mL
Study: 9089669
Drug: Clonidine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (1.5 micrograms kg‐1 in 10 ml infused intravenously over 10 min) at 20 degrees C
Study: 9089669
Drug: Clonidine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (1.5 micrograms kg‐1 in 10 ml infused intravenously over 10 min) at 40 degrees C
Study: 4013628
Drug: Centrally acting
Normalized name: Other centrally acting agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centrally acting analgesics alone
Study: 30185931
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone replacement treatment
Study: 19022123
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) administered into extraction sockets
Study: 16798622
Drug: subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous recombinant interleukin-2 (rIL-2) plus antiretroviral therapy (ART)
Study: 14714359
Drug: Jiexiao Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiexiao Oral Liquid (JXOL)
Study: 14714359
Drug: Virazole (10-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virazole (10-15 mg.kg-1.d-1)
Study: 9363044
Drug: Abecarnil (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abecarnil (high dosage)
Study: 9363044
Drug: Abecarnil (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abecarnil (low dosage)
Study: 1526085
Drug: Bendroflumethiazide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendroflumethiazide (5 mg daily for 1 week)
Study: 1526085
Drug: Transbuccal nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transbuccal nitroglycerin (0.25 mg)
Study: 29776960
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (2.5 mg), vitamin B6 (50 mg), vitamin B12 (1 mg)
Study: 18950439
Drug: 4% lidocaine
Normalized name: Lidocaine 344 mg TOPICAL PATCH [Pain Relief 4% Lidocaine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% lidocaine (active) injections
Study: 18950439
Drug: saline (control)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: saline (control) injections
Study: 12598775
Drug: Nevirapine 200
Normalized name: nevirapine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine 200 mg once weekly (cohort A, n = 12)
Study: 12598775
Drug: Nevirapine 200
Normalized name: nevirapine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine 200 mg twice weekly (cohort B, n = 12)
Study: 12598775
Drug: Nevirapine 200
Normalized name: nevirapine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine 200 mg every other day (cohort C, n = 9)
Study: 8604065
Drug: Conventional buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional buccal approach
Study: 1782718
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg preoperatively and 50 mg post-operatively
Study: 1782718
Drug: Diclofenac 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 100 mg post-operatively only
Study: 6451354
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment (urea vehicle)
Study: 31751935
Drug: Ketone salt
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketone salt (KS) supplement (0.38 g/kg body mass)
Study: 25163489
Drug: Dexamethasone 12
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 12 mg intramuscularly, two doses 24 hours apart
Study: 25163489
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care without steroids
Study: 24008568
Drug: 1 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 µg/kg remifentanil
Study: 24008568
Drug: 2 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 µg/kg remifentanil
Study: 7581113
Drug: Cytokine-mediated immunotherapy
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokine-mediated immunotherapy
Study: 2198301
Drug: Buspirone 5-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 5-30 mg/day
Study: 25545376
Drug: Ferric maltol
Normalized name: Ferric Maltol
DrugBank: Ferric maltol (DB15598)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ferric maltol (30 mg twice a day)
Study: 25202177
Drug: Kinesio Taping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesio Taping (KT) combined with conventional physical therapy (n=20)
Study: 25202177
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy only (n=20)
Study: 11752036
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (4000 mg)
Study: 11752036
Drug: Control oil
Normalized name: SALICYLIC ACID 29.2 mg TOPICAL LIQUID [Acne Control oil-free Cleansing]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control oil (4000 mg)
Study: 9056732
Drug: Traditional diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional diet and yogurt combination
Study: 7686187
Drug: 0.025% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% tretinoin cream applied once daily for 9 months
Study: 7686187
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream applied once daily for 9 months
Study: 3523043
Drug: Adjuvant chemo-immunotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemo-immunotherapy (BCG or BCG plus tumor cell vaccine)
Study: 27272818
Drug: Combined active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined active groups (single-dose, repeated-dose, continuous infusion)
Study: 17610993
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied thrice weekly for 8 weeks
Study: 17610993
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied thrice weekly for 12 weeks
Study: 17610993
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied thrice weekly for both durations
Study: 17610993
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied thrice weekly
Study: 16083538
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate (MF) dry powder inhaler (DPI) 400 microg qd PM (one inhalation)
Study: 11935106
Drug: Computed tomographic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computed tomographic discography using intradiscal iodinated contrast agent
Study: 25528574
Drug: Erythropoietin 40,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin 40,000 IU administered weekly for up to three doses
Study: 25528574
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered weekly for up to three doses
Study: 9437195
Drug: Alpha-tocopherol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-tocopherol (50 mg daily)
Study: 9437195
Drug: Beta-carotene (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (20 mg daily)
Study: 2511693
Drug: 0.025 mg
Normalized name: lisuride 0.025 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025 mg nitroglycerin intravenously
Study: 4544476
Drug: Polarizing solution:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polarizing solution: continuous intravenous perfusion during 7 days of one liter daily of a 10% glucose solution with potassium (40 m Eq/L) and insulin (20 units)
Study: 4544476
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: slow perfusion (one liter daily) of a 5% glucose solution
Study: 26279580
Drug: Caffeinated energy
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated energy drink (3 mg/kg)
Study: 26693858
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg/kg)
Study: 20962338
Drug: High-dose tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tirofiban (HDT) pretreatment
Study: 20962338
Drug: Bail-out use
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bail-out use of study medication
Study: 18328334
Drug: Treatment (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (specific pharmacologic treatment not detailed)
Study: 18328334
Drug: On treatment
Normalized name: STIX 3 DAY YEAST INFECTION TREATMENT KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: On treatment (no specific intervention mentioned)
Study: 16416102
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy agents (PTA) applied five times a week for 3 weeks
Study: 16416102
Drug: Hylan G-F
Normalized name: hylan G-F 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hylan G-F 20 or sodium hyaluronate (NaHA) administered weekly intra-articular during the first 3 weeks and in the sixth month
Study: 14735021
Drug: Subarachnoid anaesthesia
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subarachnoid anaesthesia with 12.75 mg 0.5% hyperbaric bupivacaine
Study: 14735021
Drug: Subarachnoid anaesthesia
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subarachnoid anaesthesia with 12.75 mg 0.5% hyperbaric bupivacaine and 15 mg fentanyl
Study: 8615356
Drug: Synthetic beta-carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic beta-carotene (40 mg daily for 14 days)
Study: 8615356
Drug: Natural beta-carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural beta-carotene from Dunaliella bardawil (40 mg daily for 14 days)
Study: 6706069
Drug: 3-day clear
Normalized name: clear days ahead
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day clear liquid diet with laxatives and enemas
Study: 6706069
Drug: 3-day minimum-residue
Normalized name: Human t-PA (residues 1-3 and 176-527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day minimum-residue diet with laxatives and enemas
Study: 6706069
Drug: 1-day minimum-residue
Normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted 1 UNT [Xyntha]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day minimum-residue diet with laxatives and enemas
Study: 31241491
Drug: Topical nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical nifedipine 3% ointment
Study: 29297588
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments for lichen planopilaris
Study: 25318000
Drug: Propofol &
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol & sufentanil (PS) group received 0.1 μg/kg sufentanil and 1-2 mg/kg propofol
Study: 25318000
Drug: Propofol &
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol & fentanyl (PF) group received 1 μg/kg fentanyl and 1-2 mg/kg propofol
Study: 25318000
Drug: Propofol &
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol & remifentanil (PR) group received 1 μg/kg remifentanil and 1-2 mg/kg propofol
Study: 25318000
Drug: Propofol &
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol & half-fentanil (Pf) group received 0.5 μg/kg fentanyl and 1-2 mg/kg propofol
Study: 25318000
Drug: Propofol &
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol & half-sufentanil (Ps) group received 0.05 μg/kg sufentanil and 1-2 mg/kg propofol
Study: 25318000
Drug: Propofol &
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol & half-remifentanil (Pr) group received 0.5 μg/kg remifentanil and 1-2 mg/kg propofol
Study: 22318246
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose CsA
Study: 11819152
Drug: Anticholinergic drug
Normalized name: Anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic drug withdrawal
Study: 2481671
Drug: Single-agent regimens
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent regimens
Study: 31474719
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of midazolam at doses of 5, 15, and 30 µg/kg
Study: 31474719
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of midazolam at doses of 15, 50, and 100 µg/kg
Study: 31474719
Drug: Urinary excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary excretion of midazolam after oral administration
Study: 28736211
Drug: Modern neuroscience
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modern neuroscience approach (pain neuroscience education and cognition-targeted exercise therapy)
Study: 21127424
Drug: IV ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV ibuprofen 800 mg every 6 hours for 120 hours (5 days)
Study: 19455620
Drug: Ambrisentan (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan (10 mg) with Tadalafil (40 mg QD)
Study: 19455620
Drug: Tadalafil (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (40 mg) with Ambrisentan (10 mg QD)